TB500 Research Data

Natural Aminos Research Formula of the Day — TB-500

Benefits

TB-500 is the commercial name commonly used for a synthetic fragment (Ac-LKKTETQ, corresponding to amino acids 17–23) of Thymosin Beta-4 (TB4), a 43-amino-acid peptide that is the most abundant beta-thymosin in the human body. TB4 itself is well studied and plays a central role in regulating actin, the structural protein cells use to migrate and rebuild tissue, and has documented roles in promoting angiogenesis (new blood vessel formation), cell migration, and inflammation modulation.

Peer-reviewed TB4 research has shown pro-angiogenic effects in endothelial cells, accelerated cutaneous wound healing in animal models, cytoprotective effects in gingival fibroblasts, and a cardiac-remodeling benefit in mice after heart attack, where TB4 reduced fibrosis and scarring via modulation of the ROCK1 pathway. In diabetic human stem-cell-derived endothelial cells, TB4 improved cell viability, reduced markers of vascular dysfunction, and enhanced reparative potency for ischemic limb disease in an animal model. TB4 has also shown anti-inflammatory and antimicrobial adjunct effects in a corneal infection (keratitis) animal model.

Importantly, the great majority of this evidence is for full-length TB4, not TB-500 specifically. A 2026 scoping review that systematically mapped the literature found that of 80 included studies on TB4/TB-500, only a single study directly evaluated TB-500 itself — an in vitro/rat metabolite-profiling and fibroblast wound-healing screening study, not a musculoskeletal or human outcomes study.

Uses

TB4 (and, by extension, TB-500 as sold commercially) is most researched for wound healing and tissue regeneration, with the clearest human evidence in the eye and skin: TB4 ophthalmic solution has been tested in randomized, placebo-controlled Phase 2 trials for dry eye and showed significant improvement in signs and symptoms, and TB4 treatment has been studied in randomized European trials for venous leg ulcer healing. Outside those settings, TB4 has been explored preclinically for cardiac repair after myocardial infarction, bone regeneration, diabetic vascular repair, and fat-graft survival.

TB-500 specifically is marketed and used off-label by consumers and some clinics for soft-tissue and muscle injury recovery, tendon and ligament healing, and general “recovery and flexibility,” often stacked with BPC-157. This musculoskeletal use case is the most commercially promoted application of TB-500, but it is also the one with the thinnest direct evidence: the 2026 scoping review found no human interventional studies of administered TB4 or TB-500 in tendon, ligament, muscle, cartilage, or spine/disk categories at all. TB-500/TB4 is also not FDA-approved for any indication. The FDA lists the TB4 fragment (LKKTETQ, i.e., the sequence marketed as TB-500) among bulk drug substances that may present significant safety risks in compounding, citing limited human exposure and safety data, and the World Anti-Doping Agency classifies TB4 and its derivatives, including TB-500, as prohibited substances under the 2026 Prohibited List.

Published Research

Human evidence exists for full-length TB4, concentrated almost entirely in ocular and wound/skin settings. A randomized, placebo-controlled Phase 2 trial found TB4 ophthalmic solution significantly improved dry eye signs and symptoms compared to placebo. Separate randomized European trials examined TB4 for venous ulcer healing, reporting favorable safety, tolerability, and healing enhancement. A first-in-human Phase 1 randomized, placebo-controlled study of intravenous TB4 in healthy volunteers, and a separate first-in-human study of recombinant TB4 in Chinese volunteers, established basic safety and pharmacokinetics but did not test musculoskeletal or injury-recovery outcomes. A small pilot study also tested TB4-pretreated endothelial progenitor cells (not TB4 injection itself) in acute heart attack patients.

Preclinical TB4 evidence supporting the mechanisms behind popular TB-500 claims includes: promotion of directional endothelial cell migration and angiogenesis, accelerated full-thickness skin wound healing in animal and cell models, reduced cardiac fibrosis and improved remodeling after induced heart attack in mice, and expression changes suggesting a possible (but not directly tested) role in diabetic Achilles tendon repair in rats.

Direct TB-500 evidence, as distinct from TB4, is limited to a single identified study: an analytical/in vitro investigation that quantified TB-500 and its metabolites and screened for fibroblast wound-healing activity in vitro and in rats — not a controlled musculoskeletal repair or human clinical study. No randomized controlled human trial of TB-500 itself, and no human trial of TB4 or TB-500 in tendon, ligament, or muscle injury, has been identified.

Why More Research Is Needed

What's actually proven: full-length TB4 has real, randomized human trial evidence — but only in two specific niches, dry eye and venous ulcer healing, plus basic safety/pharmacokinetic data from healthy-volunteer Phase 1 studies. TB4's core mechanisms (actin regulation, angiogenesis promotion, anti-fibrotic and anti-inflammatory signaling) are well replicated across independent animal and cell studies.

What's theory, not proof: the musculoskeletal recovery use case that TB-500 is most commonly marketed and purchased for — tendon, ligament, and muscle injury repair — has essentially no direct evidence behind it. No human interventional trial of TB4 or TB-500 in tendon, ligament, or muscle tissue exists, and the animal/cell evidence in that space is sparse, heterogeneous, and largely indirect (expression studies, endogenous-marker correlations) rather than controlled treatment trials. The theoretical case is coherent — TB4's actin-regulation and cell-migration mechanisms are not tissue-specific, so it's biologically plausible that a peptide shown to help skin and corneal healing could help tendon or muscle repair too — but that is currently an extrapolation, not a demonstrated effect, and this gap is exactly why the 2026 scoping review's authors singled it out: "biologic plausibility and clinical readiness should not be treated as equivalent concepts in this area."

A second, distinct gap compounds the first: even where TB4 evidence is strongest, that evidence is for TB4, not TB-500. TB-500 is a shorter fragment/derivative sold under its own commercial identity, and only one study in the current literature has evaluated it directly. Treating TB4's human trial results as if they establish TB-500's effects is itself an unproven assumption layered on top of the unproven musculoskeletal-use assumption. Combined with FDA compounding-safety concerns and WADA's prohibited-substance classification, the honest read is: modest, narrowly-scoped human proof for the parent molecule (TB4) in eye and wound applications, and essentially no direct human or controlled proof for TB-500 itself or for the injury-recovery use case it is most often sold for.

Sources

Applied Sciences (MDPI, 2026) — Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair: A Scoping Review (McGuire, Hughes, Maak, Cushman)

Cornea (2015) — Sosne, Dunn, Kim: Thymosin β4 Significantly Improves Signs and Symptoms of Severe Dry Eye in a Phase 2 Randomized Trial

Annals of the NY Academy of Sciences (2007, 2010) — Guarnera et al.: Thymosin β4 and Venous Ulcers, European Randomized Studies

Journal of Cellular and Molecular Medicine (2021) — First-in-Human Phase I Study of Recombinant Human Thymosin β4 in Healthy Chinese Volunteers

PMC — Thymosin Beta-4 Modulates Cardiac Remodeling by Regulating ROCK1 Expression in Adult Mammals

PMC — Thymosin Beta-4 Improves Endothelial Function and Reparative Potency of Diabetic Endothelial Cells

Journal of Chromatography B (2024) — Rahaman et al.: Simultaneous Quantification of TB-500 and Its Metabolites and Wound-Healing Activity Screening (the one direct TB-500 study identified)

U.S. FDA — Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks (lists the TB4 fragment/TB-500 sequence)

World Anti-Doping Agency — The 2026 Prohibited List (TB4 and derivatives, including TB-500)

Hashtags

#Peptidetherapy #PeptideResearch #PeptideScience #Biohacking #ResearchPeptides #ScienceBased #TB500 #ThymosinBeta4 #RecoveryScience #TissueRepair #WoundHealing